SCRI Trials and Trial Regimen Updates

The following updates were completed between May 17, 2025, through June 19, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
24179	USOR 24179 BMT 56 Phase 2 Vimselitinib Q28D
23165	USOR 23165 GI 356 Phase 2 Part B FOLFIRI Q28D - v2.1 01MAR2024 USOR 23165 GI 356 Phase 2 Part B FOLFOX Q28D - v2.1 01MAR2024 USOR 23165 GI 356 Phase 2 Part B Tinengotinib Q28D - v2.1 01MAR2024
24250	USOR 24250 LUN 583 Phase 1b/2 Part 1 Telisotuzumab Adizutecan + Budigalimab Q21D USOR 24250 LUN 583 Phase 1b/2 Part 2 Arm 3 Budigalimab + Pemetrexed + Carboplatin fb Budigalimab + Pemetrexed Q21D USOR 24250 LUN 583 Phase 1b/2 Part 2 Arm 3 Budigalimab + Pemetrexed + Cisplatin fb Budigalimab + Pemetrexed Q21D USOR 24250 LUN 583 Phase 1b/2 Part 2 SOC Arm Pembrolizumab + Pemetrexed + Carboplatin fb Pembrolizumab + Pemetrexed Q21D USOR 24250 LUN 583 Phase 1b/2 Part 2 SOC Arm Pembrolizumab + Pemetrexed + Cisplatin fb Pembrolizumab + Pemetrexed Q21D
24326	USOR 24326 GI 394 Ph1b Arm A1/A2 Toripalimab-tpzi + CHS-114 Q21D
23309	USOR 23309 BRE 439 Phase 3 Arm 1 MK-2870 + Pembrolizumab Q42D 24Jan2025 USOR 23309 BRE 439 Phase 3 Arm 2 Pembrolizumab +/- Capecitabine Q42D 24Jan2025
24234	USOR 24234 GI 391 Phase 2 Arm A Casdozokitug + Toripalimab + Bevacizumab Q21D USOR 24234 GI 391 Phase 2 Arm B Casdozokitug + Toripalimab + Bevacizumab Q21D USOR 24234 GI 391 Phase 2 Arm C Toripalimab + Bevacizumab Q21D

Study Number	Notes for New Build
24155	USOR 24155 GI 385 Phase 3 Arm A Amivantamab + mFOLFOX6 Q28D USOR 24155 GI 385 Phase 3 Arm A Amivantamab + FOLFIRI Q28D USOR 24155 GI 385 Phase 3 Arm B Cetuximab D1,15 + FOLFIRI Q28D USOR 24155 GI 385 Phase 3 Arm B Cetuximab D1,15 + mFOLFOX6 Q28D USOR 24155 GI 385 Phase 3 Arm B Cetuximab D1,8,15,22 + FOLFIRI Q28D USOR 24155 GI 385 Phase 3 Arm B Cetuximab D1,8,15,22 + mFOLFOX6 Q28D
23269	USOR 23269 RM 1032 Phase 1/2 Part 1a AVZO-021 Q28D USOR 23269 RM 1032 Phase 1/2 Part 1a Food Effect Substudy AVZO-021 D-4,.2 USOR 23269 RM 1032 Phase 1/2 Part 1b Cohort B1 AVZO-021 + Fulvestrant Q28D USOR 23269 RM 1032 Phase 1/2 Part 1b Cohort B2 AVZO-021 + Palbociclib + Endocrine Therapy Q28D USOR 23269 RM 1032 Phase 1/2 Part 1b Cohort B3 AVZO-021 + Ribociclib + Endocrine Therapy Q28D USOR 23269 RM 1032 Phase 1/2 Part 1b Cohort B4 AVZO-021 + Abemaciclib + Endocrine Therapy Q28D USOR 23269 RM 1032 Phase 1/2 Part 1b Cohort B5 AVZO-021 + Sacituzumab Govitecan-hziy Q28D USOR 23269 RM 1032 Phase 1/2 Part 1b Cohort C AVZO-021 + Carboplatin Q28D USOR 23269 RM 1032 Phase 1/2 Part 2a AVZO-021 Q28D
23322	USOR 23322 LUN 563 Phase 3 Arm 1 Dato-DXd + Rilvegostomig Q21D USOR 23322 LUN 563 Phase 3 Arm 2 Rilvegostomig Q21D USOR 23322 LUN 563 Phase 3 Arm 3 Pembrolizumab Q21D
24240	USOR 24240 MULTI 95 Phase 1 Part 2 (Cohorts 3,4,5) VT3989 Q28D USOR 24240 MULTI 95 Phase 1 Part 3 Cohort A Safety Lead-In VT3989 + Nivolumab + Ipilimumab Q42D USOR 24240 MULTI 95 Phase 1 Part 3 Cohort A VT3989 + Nivolumab + Ipilimumab Q42D USOR 24240 MULTI 95 Phase 1 Part 3 Cohort B Safety Lead-In VT3989 + Osimertinib Q28D USOR 24240 MULTI 95 Phase 1 Part 3 Cohort B VT3989 + Osimertinib Q28D
24267	USOR 24267 LYM 250 Phase 3 Zanubrutinib + Sonrotoclax or Placebo Q28D

Study Number	Notes for New Build
24310	USOR 24310 GU 256 Phase 1/1b Food Effect Sub-Study (Cohort F) ORIC-944 (D-7) + Darolutamide (D-6) USOR 24310 GU 256 Phase 1/1b Food Effect Sub-Study (Cohort F) ORIC-944 + Darolutamide Q28D USOR 24310 GU 256 Phase 1/1b Part 3 (Cohorts A and C) Lead-in ORIC-944 (D-7) + Apalutamide (D-6) USOR 24310 GU 256 Phase 1/1b Part 3 (Cohorts A and C) ORIC-944 + Apalutamide Q28D USOR 24310 GU 256 Phase 1/1b Part 3 (Cohorts B and D) Lead-in ORIC-944 (D-7) + Darolutamide (D-6) USOR 24310 GU 256 Phase 1/1b Part 3 (Cohorts B and D) ORIC-944 + Darolutamide Q28D
23251	USOR 23251 BRE 442 Phase 3 Arm 1 Saruparib + Camizestrant Q28D - v2.0 30JAN2024 USOR 23251 BRE 442 Phase 3 Arm 2 CDK4/6i + ET Q28D - v2.0 30JAN2024 USOR 23251 BRE 442 Phase 3 Arm 3 Camizestrant + CDK4/6i Q28D - v2.0 30JAN2024
24064	USOR 24064 MULTI 90 Phase 1b Zongertinib + T-DM1 Q21D - v4.0 25FEB2025 USOR 24064 MULTI 90 Phase 1b Zongertinib + T-DXd Q21D - v4.0 25FEB2025 USOR 24064 MULTI 90 Phase 1b Zongertinib + Trastuzumab + Capecitabine Q21D - v4.0 25FEB2025 USOR 24064 MULTI 90 Phase 1b Zongertinib + Trastuzumab Q21D - v4.0 25FEB2025
24301	USOR 24301 BRE 452 Phase 2 All Arms Adjuvant T-DM1 Q21D - 28APR2025 USOR 24301 BRE 452 Phase 2 Arm A Neoadjuvant Zanidatamab + Paclitaxel Q21D - 28APR2025 USOR 24301 BRE 452 Phase 2 Arm B Neoadjuvant Zanidatamab + Docetaxel + Carboplatin Q21D - 28APR2025 USOR 24301 BRE 452 Phase 2 Arm C Adjuvant Trastuzumab +/- Pertuzumab Q21D - 28APR2025 USOR 24301 BRE 452 Phase 2 Arm C Neoadjuvant Trastuzumab + Pertuzumab + Docetaxel + Carboplatin Q21D - 28APR2025 USOR 24301 BRE 452 Phase 2 Arms A and B Adjuvant Zanidatamab Q21D - 28APR2025

Updated Reference Information

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
23120	N/A	N/A	Added monotherapy regimen
23239	Amendment 06: 03 Mar 2025	N/A	N/A
23190	Amendment 03: 12 Sep 2024	N/A	Updated premedication
23085	Amendment 3.0: 08JAN2025	N/A	Added new regimen
23297	(Subprotocol A) Amendment 4: 29 Jan 2025 (Master Protocol) Amendment 4: 29 Jan 2025	N/A	Updated premedication instruction.
23294	N/A	N/A	Drug procurement updated
23190	N/A	N/A	Drug procurement updated
23292	Amendement v18: 24 Feb 2025	N/A	Added New Cohort
24004	Amendment V4.0: 14 FEB 2025	Updated observation wording	Updated drug preparation
22249	Amendment v6.0: 27 Nov 2024	N/A	Updated order of administration
23288	N/A	N/A	Updated drug procurement
23243	N/A	N/A	Updated drug procurement
24093	Version 3.0: 29 Nov 2024	N/A	Updated drug instruction
24130	N/A	N/A	Updated drug preparation

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
24153	N/A	N/A	Updated drug formulation
23307	Sub B PA3: 24 Jan 2025	N/A	N/A
23273	Amendment 4 Version 5.0	N/A	Updated drug administration
23049	PA V4: 12 AUGUST 2024	N/A	N/A
23288	a3, v4.0: 14Mar2025	N/A	Updated infusion time. Added new cohort
24146	N/A	N/A	Updated drug instructions.
24068	PA v4.0: 13 Mar 2025	N/A	Updated drug instructions.
21270	PA V8.0: 24 Jan 2025	N/A	N/A
23223	Version 7.0: 02 Apr 2025; Local Amendment 05: 07 Apr 2025	N/A	Updated drug name
21533	PA5 v6.0: 22 Jan 2025	N/A	Added new regimen
22252	Master PA5: 14 Nov 2024	N/A	N/A
24014	PA1: 31 Mar 2025	N/A	Updated drug instructions.
24099	Version 4.0, 29APR2025	N/A	Update administration instruction
22026	N/A	N/A	Updated drug name
24050	N/A	N/A	New phase open
24111	PA3.0: 28 Feb 2025.	N/A	N/A
24004	N/A	N/A	Updated stability

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
22159	N/A	N/A	Updated drug administration
23170	Version 5, 24APR2025	N/A	Added new regimen
23129	Version 5.0, 29APR2025	N/A	Added standard wording to drug instructions
24070	Memo, 07APR2025	N/A	Updated drug dose